RhumbLine Advisers
LEGN icon

RhumbLine Advisers’s Legend Biotech LEGN Stock Holding History

RhumbLine Advisers’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$435K Sell
15,067
-4,688
-24% -$126K ﹤0.01% 2854
2026
Q1 		$357K Sell
19,755
-467
-2% -$8.9K ﹤0.01% 2811
2025
Q4 		$440K Hold
20,222
– – ﹤0.01% 2749
2025
Q3 		$659K Sell
20,222
-7,127
-26% -$263K ﹤0.01% 2502
2025
Q2 		$971K Sell
27,349
-680
-2% -$22K ﹤0.01% 2263
2025
Q1 		$951K Buy
28,029
+391
+1% +$14K ﹤0.01% 2195
2024
Q4 		$899K Buy
27,638
+1,544
+6% +$64K ﹤0.01% 2301
2024
Q3 		$1.27M Sell
26,094
-240
-0.9% -$12.8K ﹤0.01% 2138
2024
Q2 		$1.17M Buy
26,334
+2,704
+11% +$125K ﹤0.01% 2158
2024
Q1 		$1.33M Buy
23,630
+715
+3% +$43.1K ﹤0.01% 2104
2023
Q4 		$1.38M Buy
22,915
+920
+4% +$58.3K ﹤0.01% 2097
2023
Q3 		$1.48M Buy
21,995
+7,530
+52% +$523K ﹤0.01% 2010
2023
Q2 		$999K Buy
+14,465
New +$945K ﹤0.01% 2290

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

RhumbLine Advisers's LEGN Position: Q2 2026 in Review

RhumbLine Advisers reduced its Legend Biotech (LEGN) stake by 24% in Q2 2026, selling an estimated $126K and leaving 15,067 shares worth $435K. The position accounts for ﹤0.01% of the portfolio, ranked #2854.

RhumbLine Advisers first reported a position in LEGN in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.48M in Q3 2023. 218 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • RhumbLine Advisers held 15,067 shares of Legend Biotech worth $435K as of Q2 2026.
  • RhumbLine Advisers sold 4,688 Legend Biotech shares in Q2 2026, an estimated $126K.
  • Legend Biotech made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2854 holding.
  • RhumbLine Advisers first reported a position in Legend Biotech in Q2 2023 and has held it in 13 quarters since.
  • RhumbLine Advisers's Legend Biotech position peaked at $1.48M in Q3 2023.
  • 218 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.